A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

  title={A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.},
  author={Antonio Waldo Zuardi and Jos{\'e} Alexandre S. Crippa and Jaime Eduardo Cecilio Hallak and Sagnik Bhattacharyya and Zerrin Atakan and Roc{\'i}o Mart{\'i}n-Santos and Philip K. McGuire and Francisco Silveira Guimar{\~a}es},
  journal={Current pharmaceutical design},
  volume={18 32},
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal… 

Tables from this paper

A systematic review of the antipsychotic properties of cannabidiol in humans
The development of Cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms
A largely affirmative body of evidence is found asserting CBD’s antipsychotic efficacy, with particular emphasis on its prevention of the hydrolysis and reuptake of the endogenous cannabinoid, anandamide.
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
CBD is an useful and promising molecule that may help patients with a number of clinical conditions and should bring important answers in the near future and support the translation of research findings to clinical settings.
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Recent in vivo studies indicating that the mechanisms responsible for CBD therapeutic potential are not unitary but rather depend on the behavioural response being measured suggest activation of TRPV1 channels may help to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD.
Could cannabidiol be used as an alternative to antipsychotics?
  • M. Fakhoury
  • Psychology, Medicine
    Journal of psychiatric research
  • 2016
Cannabidiol as a potential treatment for psychosis
CBD, a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action and the prospects of CBD as a possible novel treatment for psychotic disorders are set out.
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
  • E. Perucca
  • Medicine, Psychology
    Journal of epilepsy research
  • 2017
There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes, for the first time, according to currently available information.
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
Results from these studies are promising and suggest that CBD may have a role in the development of new therapeutic strategies in mental diseases, and they justify an in-depth commitment in this field.


Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD and confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
  • A. Zuardi
  • Biology, Medicine
    Revista brasileira de psiquiatria
  • 2008
In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of great therapeutic interest, but still waiting to be confirmed by clinical trials.
[Therapeutical use of the cannabinoids in psychiatry].
Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions, and Delta(9)-tetrahydrocannabinol and its analogues were shown to have anxIOlytic effects in the treatment of cannabis dependence.
Safety and side effects of cannabidiol, a Cannabis sativa constituent.
In vivo and in vitro reports of CBD administration across a wide range of concentrations suggest controlled CBD may be safe in humans and animals, but further studies are needed to clarify reported in vitro and in vivo side effects.
Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
It is confirmed that THC can induce a transient, acute psychotic reaction in psychiatrically well individuals and the extent of the psychotic reaction was not related to the degree of anxiety or cognitive impairment.
Cannabidiol monotherapy for treatment-resistant schizophrenia
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Effects of cannabidiol in animal models predictive of antipsychotic activity
CBD has a pharmacological profile compatible with that of an “atypical” antipsychotic agent, though the mechanism of action is uncertain and may not be identical to that of the dopamine antagonists.
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.